Evidence map›Paper›PMID 41684293›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome.

Zhengquan Zhu, Yihan Wang, Haiyun Chen, Xinye Yu, Tingyu Wang, Yajing Weng, Meihong Guo, Ying Huang, Gaojian Tao, Wangsen Cao and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhengquan ZhuDepartment of Pain Management, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yihan WangDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Haiyun ChenDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Xinye YuDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Tingyu WangDepartment of Pain Management, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yajing WengDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Meihong GuoDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Ying HuangDepartment of Pain Management, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Gaojian TaoDepartment of Pain Management, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Wangsen CaoDepartment of Nephrology, Yangzhou Precision Research Institute of Kidney Disease, Northern Jiangsu People's Hospital, Teaching Hospital of Nanjing University Medical School, Yangzhou, China.
Yong WangDepartment of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.
Daojuan WangDepartment of Pain Management, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.ORCID https://orcid.org/0000-0002-6608-7984

Funding

National Natural Science Foundation of China 82201795National Natural Science Foundation of China 82470749National Natural Science Foundation of China 82471675
6 · The paper itself

Abstract

Persistent androgen receptor (AR) activation is an important contributor to polycystic ovary syndrome (PCOS) and is affected by transcriptional regulation via histone acetylation; however, the underlying mechanisms are partially understood. This study demonstrated that AR activation in ovarian granulosa cells (GCs) of both dehydroepiandrosterone (DHEA) and high-fat diet-induced PCOS mouse models correlated with a significant increase in the histone acetyltransferase p300 and histone acetylation. Conversely, GC-specific p300 knockout or pharmacological inhibition with C646/A-485 effectively reduced AR activation, histone 3 acetylation (H3K18ac/H3K27ac), and ovarian fibrosis in PCOS mice, highlighting p300 as a critical driver. ATAC-seq and RNA-seq identified "open" chromatin regions at the AR promoter in PCOS ovaries, corresponding with increased AR transcription and histone acetylation. p300, along with transcription factor SP1 and the acetyl-reader BRD4, bound to H3K18ac and H3K27ac of the AR promoter in PCOS-modeled ovaries and GCs, which was blocked by C646 and the SP1 inhibitor Plicamycin, respectively. Importantly, continuous AR activation by its ligand DHT largely diminished the anti-fibrotic and ovarian-protective effects of C646. These findings suggest that p300, SP1, and BRD4, form a critical transcriptional complex driving AR activation and PCOS development, and that targeting the p300/AR axis may present a promising therapeutic approach for treating PCOS.

Indexed as

Cell Cycle ProteinsE1A-Associated p300 ProteinPolycystic Ovary SyndromeReceptors, AndrogenSp1 Transcription FactorTranscription FactorsAcetylationAnimalsBromodomain Containing ProteinsDisease Models, AnimalFemaleGranulosa CellsHumansMiceNuclear Proteinsp300-CBP Transcription FactorsBrd4 protein, mouseBromodomain Containing ProteinsCell Cycle ProteinsE1A-Associated p300 ProteinEp300 protein, mouseNuclear Proteinsp300-CBP Transcription FactorsReceptors, AndrogenSp1 Transcription FactorTranscription Factorsacetylation modificationandrogen receptorp300PCOSSP1

Identifiers

PMID41684293
PMCPMC13104117

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.